Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
Split congressional control will result in more drug pricing talk, but don’t expect much action.
Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
Over industry objections, a Medicare panel endorses patient symptom reporting tools that could lower payments for drugs with a high side-effect burden.